Jpmorgan Chase & CO Immix Biopharma, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Immix Biopharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 35 shares of IMMX stock, worth $86. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35
Previous 38
7.89%
Holding current value
$86
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding IMMX
# of Institutions
27Shares Held
2.67MCall Options Held
0Put Options Held
0-
Bleichroeder LP New York, NY850KShares$2.11 Million0.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA699KShares$1.73 Million0.0% of portfolio
-
Lynwood Capital Management Inc.405KShares$1 Million11.13% of portfolio
-
Geode Capital Management, LLC Boston, MA161KShares$399,5650.0% of portfolio
-
Morgan Stanley New York, NY125KShares$309,7990.0% of portfolio
About Immix Biopharma, Inc.
- Ticker IMMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,910,100
- Market Cap $34.5M
- Description
- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...